Developer docs
API playgroundTry for free, no card

Search company profiles

Clovis Oncology

Full company profile

uuid000a3pr

Namestring
Clovis Oncology
Websiteurl
clovisoncology.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Clovis Oncology is a publicly traded biopharmaceutical company focused on acquiring, developing, and commercializing cancer treatments. Founded in 2009 and headquartered in Boulder, Colorado, the company operates as a for-profit specialty oncology developer listed on NASDAQ under the ticker CLVS. The firm's stated business model centers on identifying oncology assets, advancing them through development, and bringing them to market as commercial therapeutics.

The company's organizational footprint spans 101 to 250 employees, consistent with a commercial-stage or late-clinical-stage biopharmaceutical operation. Its executive team is structured for regulatory-driven pharmaceutical commercialization, with dedicated leadership for Regulatory Affairs & Technology Operations, Human Resources, Legal (General Counsel), and Finance (CFO), under President and CEO Patrick Mahaffy. The early capitalization reflects confidence from top-tier healthcare venture investors, including a $145 million Series A in May 2009 led by a consortium of Aberdare Ventures, Abingworth, Domain Associates, Frazier Healthcare Partners, New Enterprise Associates, ProQuest Investments, and Versant Ventures, followed by strategic investment from Pfizer Venture Investments and Aisling Capital in 2011.

The commercial mechanics of Clovis Oncology's business — specific drug products in market, pricing models, distribution channels, payer mix, and revenue mechanics — are not disclosed in the available source material. The company's short description frames its model as acquiring, developing, and commercializing cancer treatments, implying a hybrid of in-licensing and internal development with subsequent specialty or broad oncology distribution, but the absence of product-level, pricing, or channel detail in the input data limits further specificity.

Short descriptiontext

Clovis Oncology is a publicly traded biopharmaceutical company that acquires, develops, and commercializes cancer treatments. Founded in 2009 and headquartered in Boulder, Colorado, the company focuses on bringing oncology therapeutics to market under NASDAQ ticker CLVS.

Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoulder, United States
HQ citystring
Boulder
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oncology drug development, cancer therapeutics, targeted oncology treatments, biopharmaceutical products, precision cancer therapy
Industry1 code
1Oncology Specialty Pharmaceuticals
CodeHLAIACAAPrimaryYes
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Pharmaceuticals
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Clovis Oncology is a biopharmaceutical company that acquires, develops, and commercializes oncology treatments for cancer patients. The company focuses on identifying, in-licensing, and advancing novel cancer therapeutics through clinical development and regulatory approval, ultimately bringing approved products to market.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Cancer treatments portfolio
CategoryOncology Pharmaceuticals
Description

Acquired, developed, and commercialized oncology therapeutics for the treatment of various cancer types, targeting oncologists, hospitals, and cancer treatment centers.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1MEI Pharma
TypeDirect peer
Description

Clinical-stage oncology biopharmaceutical company developing cancer therapies. Comparable in therapeutic focus and development-stage specialty pharma positioning.

2Spectrum Pharmaceuticals
TypeDirect peer
Description

Specialty oncology biopharmaceutical company focused on acquiring, developing, and commercializing cancer treatments. Highly comparable business model and therapeutic focus.

3Exelixis
TypeDirect peer
Description

Specialty oncology biopharmaceutical company focused on developing and commercializing cancer treatments. Comparable in therapeutic focus and commercial-stage oncology business model.

4Incyte Corporation
TypeBroad incumbent
Description

Larger specialty biopharmaceutical company with significant oncology franchise alongside other therapeutic areas. Comparable as an oncology-focused commercial-stage biopharma with broader portfolio.

5CytomX Therapeutics
TypeEmerging player
Description

Clinical-stage oncology biopharmaceutical company developing novel cancer therapeutics. Comparable therapeutic focus at earlier development stage.

6Pieris Pharmaceuticals
TypeEmerging player
Description

Clinical-stage biopharmaceutical company with oncology-focused pipeline. Comparable in therapeutic focus and biopharma development model.

7Seagen (Seattle Genetics)
TypeBroad incumbent
Description

Established oncology-focused biopharmaceutical company developing and commercializing cancer therapeutics. Comparable therapeutic focus and specialty pharma business model.

8Puma Biotechnology
TypeDirect peer
Description

Specialty biopharma focused on oncology drug development and commercialization. Comparable in scale, therapeutic focus, and clinical/commercial-stage operating model.

9Rigel Pharmaceuticals
TypeDirect peer
Description

Specialty biopharmaceutical company developing oncology and immunology treatments. Comparable in scale, therapeutic adjacency, and commercial-stage operations.

10Halozyme Therapeutics
TypeDirect peer
Description

Biopharmaceutical company with oncology-focused product portfolio and proprietary drug delivery technology. Comparable as a specialty oncology biopharma.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Clovis Oncology

Oncology Pharmaceuticalsclovisoncology.com

Clovis Oncology is a publicly traded biopharmaceutical company that acquires, develops, and commercializes cancer treatments. Founded in 2009 and headquartered in Boulder, Colorado, the company focuses on bringing oncology therapeutics to market under NASDAQ ticker CLVS.

What Clovis Oncology does

Clovis Oncology is a publicly traded biopharmaceutical company focused on acquiring, developing, and commercializing cancer treatments. Founded in 2009 and headquartered in Boulder, Colorado, the company operates as a for-profit specialty oncology developer listed on NASDAQ under the ticker CLVS. The firm's stated business model centers on identifying oncology assets, advancing them through development, and bringing them to market as commercial therapeutics.

The company's organizational footprint spans 101 to 250 employees, consistent with a commercial-stage or late-clinical-stage biopharmaceutical operation. Its executive team is structured for regulatory-driven pharmaceutical commercialization, with dedicated leadership for Regulatory Affairs & Technology Operations, Human Resources, Legal (General Counsel), and Finance (CFO), under President and CEO Patrick Mahaffy. The early capitalization reflects confidence from top-tier healthcare venture investors, including a $145 million Series A in May 2009 led by a consortium of Aberdare Ventures, Abingworth, Domain Associates, Frazier Healthcare Partners, New Enterprise Associates, ProQuest Investments, and Versant Ventures, followed by strategic investment from Pfizer Venture Investments and Aisling Capital in 2011.

The commercial mechanics of Clovis Oncology's business — specific drug products in market, pricing models, distribution channels, payer mix, and revenue mechanics — are not disclosed in the available source material. The company's short description frames its model as acquiring, developing, and commercializing cancer treatments, implying a hybrid of in-licensing and internal development with subsequent specialty or broad oncology distribution, but the absence of product-level, pricing, or channel detail in the input data limits further specificity.

Clovis Oncology firmographics

Firmographics
Name
Clovis Oncology
Website
https://clovisoncology.com
Company type
Private
Founded year
2009
Headcount range
101–250 employees
Short description
Clovis Oncology is a publicly traded biopharmaceutical company that acquires, develops, and commercializes cancer treatments. Founded in 2009 and headquartered in Boulder, Colorado, the company focuses on bringing oncology therapeutics to market under NASDAQ ticker CLVS.
Ownership category
akta.pro rank

Clovis Oncology industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

  • Oncology drug development
  • Cancer therapeutics
  • Targeted oncology treatments
  • Biopharmaceutical products
  • Precision cancer therapy

Where Clovis Oncology is headquartered

Location

Headquarters

HQ city
Boulder
HQ country
United States
HQ region
North America

Markets served

Clovis Oncology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Clovis Oncology product offering

Product offering

Core offering

Clovis Oncology is a biopharmaceutical company that acquires, develops, and commercializes oncology treatments for cancer patients. The company focuses on identifying, in-licensing, and advancing novel cancer therapeutics through clinical development and regulatory approval, ultimately bringing approved products to market.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cancer treatments portfolio Acquired, developed, and commercialized oncology therapeutics for the treatment of various cancer types, targeting oncologists, hospitals, and cancer treatment centers.

Companies that use Clovis Oncology

Customer profile

Ideal customer profiles2 records

Clovis Oncology technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Clovis Oncology partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights2 records

Clovis Oncology competitors and assessment

Company assessment

Direct peers

  • MEI Pharma: Clinical-stage oncology biopharmaceutical company developing cancer therapies. Comparable in therapeutic focus and development-stage specialty pharma positioning.
  • Spectrum Pharmaceuticals: Specialty oncology biopharmaceutical company focused on acquiring, developing, and commercializing cancer treatments. Highly comparable business model and therapeutic focus.
  • Exelixis: Specialty oncology biopharmaceutical company focused on developing and commercializing cancer treatments. Comparable in therapeutic focus and commercial-stage oncology business model.
  • Puma Biotechnology: Specialty biopharma focused on oncology drug development and commercialization. Comparable in scale, therapeutic focus, and clinical/commercial-stage operating model.
  • Rigel Pharmaceuticals: Specialty biopharmaceutical company developing oncology and immunology treatments. Comparable in scale, therapeutic adjacency, and commercial-stage operations.
  • Halozyme Therapeutics: Biopharmaceutical company with oncology-focused product portfolio and proprietary drug delivery technology. Comparable as a specialty oncology biopharma.

Broad incumbents

  • Incyte Corporation: Larger specialty biopharmaceutical company with significant oncology franchise alongside other therapeutic areas. Comparable as an oncology-focused commercial-stage biopharma with broader portfolio.
  • Seagen (Seattle Genetics): Established oncology-focused biopharmaceutical company developing and commercializing cancer therapeutics. Comparable therapeutic focus and specialty pharma business model.

Emerging players

  • CytomX Therapeutics: Clinical-stage oncology biopharmaceutical company developing novel cancer therapeutics. Comparable therapeutic focus at earlier development stage.
  • Pieris Pharmaceuticals: Clinical-stage biopharmaceutical company with oncology-focused pipeline. Comparable in therapeutic focus and biopharma development model.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Clovis Oncology social profiles

Digital presence

Clovis Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Clovis Oncology leadership team

Management profile

Number of profiles

Profiles5 records

Clovis Oncology funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Clovis Oncology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clovis Oncology

What does Clovis Oncology do?

Clovis Oncology is a biopharmaceutical company that acquires, develops, and commercializes oncology treatments for cancer patients. The company focuses on identifying, in-licensing, and advancing novel cancer therapeutics through clinical development and regulatory approval, ultimately bringing approved products to market.

When was Clovis Oncology founded?

Clovis Oncology was founded in 2009. It employs 101 to 250 people.

Where is Clovis Oncology based?

Clovis Oncology is headquartered in Boulder, United States, in the North America region.

Who are Clovis Oncology's main competitors?

Direct peers on record are MEI Pharma, Spectrum Pharmaceuticals, Exelixis, Puma Biotechnology, Rigel Pharmaceuticals and Halozyme Therapeutics. Broad incumbents are Incyte Corporation and Seagen (Seattle Genetics). Emerging players are CytomX Therapeutics and Pieris Pharmaceuticals.

Does Clovis Oncology have an API?

No public API is recorded for Clovis Oncology.

What industry is Clovis Oncology in?

Clovis Oncology's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Drug Development and DeliveryAvila Announces Allowance of IND Application for Oral EGFR Mutant-Selective InhibitorAvila Therapeutics announced that the US FDA allowed its IND application for CO-1686, an oral EGFR mutant-selective inhibitor developed in alliance with Clovis Oncology, triggering a $4 million milestone payment. Initial Phase I/II clinical studies for the drug are expected to begin in the US and Europe in the second quarter of 2012, followed by trials in Asia. This development marks the second clinical candidate from Avila's proprietary Avilomics platform, targeting non-small cell lung cancer patients with specific EGFR mutations.NejmRucaparib or Physician’s Choice in Metastatic Prostate CancerThe phase 3 TRITON3 trial demonstrated that the PARP inhibitor rucaparib significantly prolonged imaging-based progression-free survival compared to physician's choice of control therapy (docetaxel or a second-generation androgen-receptor pathway inhibitor) in patients with metastatic, castration-resistant prostate cancer harboring BRCA or ATM alterations. In the BRCA subgroup, median progression-free survival was 11.2 months with rucaparib versus 6.4 months with control (hazard ratio 0.50), while the intention-to-treat population showed 10.2 months versus 6.4 months (hazard ratio 0.61). The trial enrolled 405 patients at 143 sites across 12 countries and was funded by Clovis Oncology, with the greatest treatment benefit observed in patients with BRCA2 alterations.BenzingaWhy Clovis Oncology (CLVS) Stock Is Plunging TodayClovis Oncology Inc has voluntarily filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court and will sell its assets through a court-supervised process. The company secured up to $75 million in debtor-in-possession financing and entered into a stalking horse purchase agreement with Novartis Innovative Therapies AG for its FAP-2286 asset, receiving $50 million upfront with potential additional milestones of up to $333.75 million and $297 million in sales milestones. Clovis shares fell 11.50% to $0.18 during premarket trading as the company continues discussions with other parties for potential asset sales.BenzingaWhy Clovis Oncology (CLVS) Shares Are Plunging TodayClovis Oncology Inc reported a Q3 EPS loss of $(0.39) on sales of $30.66 million, down from $37.92 million a year ago, while shares dropped approximately 75.60%. The company disclosed in its Q3 SEC filing that it will not have sufficient liquidity to maintain operations beyond January 2023 based on current cash of $58.30 million and declining Rubraca revenues. Clovis is actively pursuing a potential sub-licensing arrangement for Rubraca outside the U.S. and is in discussions to sell license rights to FAP-2286 to address its capital needs.BenzingaClovis Oncology's Rubraca Hits Primary Goal In Prostate Cancer SettingsClovis Oncology announced positive topline results from the Phase 3 TRITON3 trial showing Rubraca monotherapy significantly improved radiographic progression-free survival compared to control in prostate cancer patients. The trial achieved statistical significance with a hazard ratio of 0.50, demonstrating median PFS of 11.2 months for BRCA mutation patients versus 6.4 months for the control group. The company plans to submit a supplemental marketing application to the FDA in Q1 2023 for the BRCA subgroup of patients.BenzingaClovis Oncology's Flagship Ovarian Cancer Drug Improves Progression-Free Survival As First-Line MaintenanClovis Oncology announced results from a subgroup analysis of the Phase 3 ATHENA trial showing that Rubraca as a first-line maintenance treatment improved progression-free survival versus placebo in advanced ovarian cancer patients across all risk subgroups. In HRD-positive patients with complete response to chemotherapy, Rubraca achieved a median PFS of 25.8 months compared to 6.4 months for placebo in the intent-to-treat population. Safety profiles were similar between treatment and placebo subgroups, and CLVS shares rose 13% in premarket trading following the announcement.BenzingaWhy Clovis Oncology (CLVS) Shares Are Falling TodayClovis Oncology Inc reported it will need to raise additional capital in the near term to fund operations and continue as a going concern beyond February 2023, after its reverse stock split proposal failed to pass due to insufficient shareholder support. The company held $94.6 million in cash while Q2 Rubraca sales declined 13% year-over-year to $32.1 million, with COVID continuing to impact second-line maintenance treatment. Clovis is now exploring alternatives including partnering development and commercialization rights to FAP-2286 and is in preliminary discussions with potential partners.PR NewswireThinking about buying stock in Humanigen, Endo International, Kura Oncology, Delta Air Lines, or Clovis Oncology?InvestorsObserver issued PriceWatch Alerts for stocks including Humanigen, Endo International, Kura Oncology, Delta Air Lines, and Clovis Oncology. The alerts utilize a proprietary scoring system evaluating short-term technical, long-term technical, and fundamental factors to determine investment suitability. This announcement serves as a promotional disclosure for the InvestorsObserver service.PR NewswireThinking about buying stock in Energy Focus, Ford Motor, Clovis Oncology, Li Auto, or Rigel Pharmaceuticals?InvestorsObserver issued PriceWatch Alerts for Energy Focus, Ford Motor, Clovis Oncology, Li Auto, and Rigel Pharmaceuticals on June 22, 2022. The alerts utilize a proprietary scoring methodology that evaluates short-term technical, long-term technical, and fundamental factors to determine investment suitability. This serves as an informational update for investors regarding these specific stock tickers.PR NewswireThinking about buying stock in Vinco Ventures, Digital Brands, Endo, Clovis Oncology, or Under Armour?InvestorsObserver issued PriceWatch Alerts for the stocks of Vinco Ventures, Digital Brands, Endo, Clovis Oncology, and Under Armour. The alerts utilize a proprietary scoring methodology that evaluates short-term technical, long-term technical, and fundamental factors to determine investment suitability.